Actimmune
(interferon gamma-1b)Phase 2Small molecule
Interferon gamma-1b is used to treat certain serious infections and a rare genetic disorder called chronic granulomatous disease, where the body's immune system doesn't work properly to fight off infections.[1] Actimmune is currently being investigated across 4 indications[3], with its most advanced program in Phase 2.[1]
Actimmune is one of 85 small molecule programs targeting Hepatic fibrosis. It is currently in Phase 2.
4
Indications
30
Total Trials
2
Active Trials
84
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cellcept
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Idiopathic Pulmonary Fibrosis4 trials
Safety and Efficacy3 trials
Cystic Fibrosis2 trials
19 more indications
Cryptococcal Meningitis1 trial
Unresectable1 trial
Macular Edema1 trial
Osteopetrosis1 trial
ACTIMMUNE in Intermediate Osteopetrosis
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT02666768·5 enrolled
Necrosis1 trial
A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001004·30 enrolled
Hepatitis C1 trial
Immune1 trial
Friedreich ataxia1 trial
Interferon Gamma-1b in Friedreich Ataxia (FRDA)
Completed·—·Phase 2·NCT01965327·12 enrolled
Bronchiolitis Obliterans1 trial
Children1 trial
Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000761·20 enrolled
Mycosis Fungoides1 trial
Sepsis1 trial
Acute Myeloid Leukemia1 trial
Regulatory
FDA Approval Timeline[4]
Feb 25, 1999
ACTIMMUNE
BLA BLA103836
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for interferon gamma-1b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interferon Gamma Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHorizon Therapeutics Ireland DAC